Journal of Thoracic Oncology最新文献

{"title":"Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.","authors":"Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee, Casilda Llácer Pérez, Filippo De Braud, Eric B Haura, Rachel E Sanborn, James Chih-Hsin Yang, Catherine A Shu, Koichi Goto, Makoto Nishio, Jun Zhao, Zhijie Wang, Pascale Tomasini, Enriqueta Felip, Jonathan W Goldman, Sai-Hong Ignatius Ou, Michael Boyer, Grace Gao, Siyang Qu, Joshua C Curtin, Xuesong Lyu, Robert W Schnepp, Priya Kim, Meena Thayu, Roland E Knoblauch, Patricia Lorenzini, Mahadi Baig, Alexander I Spira, Natasha B Leighl","doi":"10.1016/j.jtho.2025.05.012","DOIUrl":"10.1016/j.jtho.2025.05.012","url":null,"abstract":"<p><strong>Introduction: </strong>Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity. We assessed the safety and efficacy of amivantamab in participants with advanced NSCLC harboring primary MET exon 14 skipping mutations (METex14).</p><p><strong>Methods: </strong>CHRYSALIS enrolled participants with METex14 NSCLC who progressed after or declined standard-of-care therapy. Participants received intravenous amivantamab weekly for 4 weeks and biweekly thereafter. Objective response rate, duration of response (DoR), clinical benefit rate, progression-free survival, overall survival, safety, and circulating tumor DNA were analyzed.</p><p><strong>Results: </strong>Among 97 participants, 16 were treatment naive, 28 received prior treatment without MET therapies, and 53 received prior MET therapies. Objective response rate was 32% overall, 50% in treatment-naive participants, 46% in participants without prior MET therapies, and 19% in participants with prior MET therapies. In participants without prior MET therapies, amivantamab activity was observed regardless of co-occurring genomic alterations. Clinical benefit rate was 69% overall, 88% in treatment-naive participants, 64% in participants without prior MET therapies, and 66% in participants with prior MET therapies. Median DoR was 11.2 months; 61% (19/31) of the responders had DoR greater than or equal to 6 months. Median progression-free survival was 5.3 months (95% confidence interval, 4.3-7.0); median overall survival was 15.8 months (95% confidence interval, 14.6-not estimable). Most common adverse events were rash (79%) and infusion-related reactions (72%), most being grades 1 to 2 (52%).</p><p><strong>Conclusions: </strong>The safety profile was consistent with previous reports of amivantamab in EGFR-mutant NSCLC. Amivantamab demonstrated clinically meaningful and durable antitumor activity in participants with METex14 advanced NSCLC, including those who progressed on prior MET therapies.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-Based Lung Cancer Screening in Clinical Practice.","authors":"Matthew M Rode, Anne-Marie G Sykes, Mark S Allen, Lori A Ingalls, Hamid Rehman, Daniel C Deetz, Susanne C Degen, Janel N Glantz, Adel Zurob, Jamil Taji, Karen L Swanson, Eric A Jensen, Laura C Pappagallo, Margaret M Johnson, Barbara L McComb, Lynn M Loosbrock, Andrew C Hanson, Ping Yang, David E Midthun","doi":"10.1016/j.jtho.2025.05.009","DOIUrl":"10.1016/j.jtho.2025.05.009","url":null,"abstract":"<p><strong>Introduction: </strong>Current U.S. lung cancer screening guidelines use only age and smoking history; however, individual risk calculators may better stratify risk.</p><p><strong>Methods: </strong>In a referred cohort design, we implemented a multisite lung cancer screening program across four states. We screened patients who qualified by either the USPSTF₂₀₁₃ criteria or a PLCO_m2012 risk of greater than or equal to 1.34%. Invasive procedures were abstracted retrospectively. We compared the incidence and prevalence of lung cancer among patients who qualified by only USPSTF₂₀₁₃ or PLCO_m2012 and along the continuum of prospective lung cancer risk using PLCO_m2012.</p><p><strong>Results: </strong>Of 2471 screened patients, 114 had lung cancer. Furthermore, 84% of all patients and 91% of patients who were diagnosed with having cancer qualified by both criteria. Prevalence of lung cancers were over 7 times higher in the 10% of the cohort with the highest prospective risk than the lowest risk 10%. Incidence of cancers were higher among patients who qualified only by PLCO_m2012 (3.6 per 1000 person-years) compared with patients who qualified only by USPSTF₂₀₁₃ (0 per 1000 person-years). Of screen-detected NSCLC, 74% was stage I or II. Three (4.5%) surgical resections were performed for screen-identified nodules which proved to be benign. Overall, 106 patients (4.3%) underwent an invasive intervention due to screening.</p><p><strong>Conclusions: </strong>Most patients qualified for lung cancer screening by both UPSTSF₂₀₁₃ and PLCO_m2012 criteria. Incidence cancers were higher among patients who qualified by PLCO_m2012 but not USPSTF₂₀₁₃ criteria. Prevalence and incidence cancer identification increased with prospective risk. Invasive procedures and resections for benign disease were relatively low.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.","authors":"Sehhoon Park, Hee Kyung Ahn, Seoyoung Lee, Young Joo Min, Jinyong Kim, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jii Bum Lee, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong","doi":"10.1016/j.jtho.2025.05.006","DOIUrl":"10.1016/j.jtho.2025.05.006","url":null,"abstract":"<p><strong>Introduction: </strong>Uncommon EGFR mutations comprise 10% to 20% of all EGFR mutations in NSCLC and generally report reduced responsiveness to EGFR tyrosine kinase inhibitors (TKIs). Lazertinib, a third-generation EGFR-TKI, has found efficacy in common EGFR mutations, but its potential in uncommon mutations remains unexplored. This study investigated the efficacy and safety of lazertinib in patients with NSCLC with uncommon EGFR mutations.</p><p><strong>Method: </strong>This single-arm, multicenter phase II trial enrolled patients with advanced NSCLC harboring uncommon EGFR mutations excluding exon 20 insertions. Patients received lazertinib 240 mg daily until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety.</p><p><strong>Results: </strong>Among 36 patients enrolled, the ORR was 50.0% (95% confidence interval [CI]: 34.5%-65.5%), with 18 partial responses, meeting the primary end point. Disease control rate was 88.9% (95% CI: 74.1%-96.2%). Patients with major uncommon mutations (G719X, L861Q, S768I) reported an ORR of 54.8% (17/31). Median PFS was 10.8 months (95% CI: 4.4-19.2), and median DoR was 15.1 months. G719X mutations reported the highest response (ORR 61%, median PFS 20.3 months), followed by S768I (ORR 60%) and L861Q (ORR 58%, median PFS 9.5 months). Treatment-emergent adverse events occurred in all patients, with grade 3 or higher events in 33.3%; most common were rash (47.2%), pruritus (36.1%), and muscle spasms (33.3%).</p><p><strong>Conclusions: </strong>Lazertinib reported promising efficacy and a manageable safety profile in patients with NSCLC with uncommon EGFR mutations, particularly for G719X, S768I, and L861Q subtypes. These results suggest lazertinib could be an effective treatment option for this heterogeneous patient population with limited therapeutic alternatives.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.","authors":"Sarah Bowen Jones, Clara Chan, Andrea R Filippi, Ken Harada, Alexander V Louie, Colin R Lindsay, Ernest Nadal, Pablo Munoz Schuffenegger, David Woolf, Corinne Faivre-Finn","doi":"10.1016/j.jtho.2025.05.004","DOIUrl":"10.1016/j.jtho.2025.05.004","url":null,"abstract":"<p><p>Precision oncology has transformed the management of NSCLC by tailoring treatment to the specific genetic alterations driving oncogenesis. Targeted therapies, such as tyrosine kinase inhibitors, have been found to dramatically improve survival in patients with advanced-stage NSCLC. However, treatment options remain limited for patients with early or locally advanced stage (I-III) NSCLC harboring driver mutations, when the disease is not resectable, or the patient is unsuitable for surgery due to poor fitness or comorbidities. There is growing interest in combining targeted therapies with radiotherapy to optimize treatment outcomes for this patient group. Notably, a progression-free survival benefit has recently been reported with the third-generation tyrosine kinase inhibitor osimertinib in patients with inoperable, EGFR-mutated, stage III NSCLC after chemoradiotherapy. A narrative review of the literature was performed using PubMed, OVID (EMBASE), and ClinicalTrials.gov to identify studies evaluating the combination of targeted therapies and radiotherapy in inoperable stages I to III NSCLC. This review provides a comprehensive overview of the incidence of actionable driver alterations and emerging clinical evidence on combining targeted therapies with thoracic radiotherapy in patients with inoperable stages I to III NSCLC. The toxicity profile of combination treatments, optimal sequencing strategies, ongoing clinical trials, and future perspectives in this field are highlighted. In summary, a clear biological rationale supports the synergistic effects of combining targeted therapies with radiotherapy in the neoadjuvant, concurrent, and adjuvant settings. Advanced clinical trial methodologies may facilitate further research in this area, particularly for rare genetic alterations, to improve outcomes for these patients.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.","authors":"Marcel Wiesweg, Ali Alaffas, Anna Rasokat, Felix Carl Saalfeld, Maximilian Rost, Christin Assmann, Franziska Herster, Moritz Hilbrandt, Frank Griesinger, Anna Kron, Julia Roeper, Franziska Glanemann, Cornelia Kropf-Sanchen, Martin Reck, Jonas Kulhavy, Albrecht Stenzinger, Jürgen Wolf, Martin Sebastian, Martin Schuler, Martin Wermke, Nikolaj Frost, Hans-Georg Kopp, Petros Christopoulos, Matthias Scheffler","doi":"10.1016/j.jtho.2025.04.016","DOIUrl":"10.1016/j.jtho.2025.04.016","url":null,"abstract":"<p><strong>Background: </strong>Targeted treatment of patients with metastatic BRAF-V600-mutated NSCLC using BRAF/MEK-inhibitors is effective but limited by acquired resistance. Patients with BRAF-mutant NSCLC may derive long-lasting benefit from immune checkpoint inhibition with programmed death-1/programmed death-ligand 1 (PD-L1) antibodies (immuno-oncology [IO]). Although IO is the preferred first-line therapy in BRAF-mutated melanoma, the optimal treatment sequence in BRAF-mutated NSCLC is not defined.</p><p><strong>Methods: </strong>This retrospective study investigated the clinical outcome of patients with metastatic BRAF-V600-mutated NSCLC diagnosed in the German national Network Genomic Medicine Lung Cancer.</p><p><strong>Results: </strong>We identified 205 patients with BRAF-V600-mutated NSCLC; 175 patients received first-line therapy with dabrafenib/trametinib (DAB/TRM, 65.1%), IO alone (19.4%), or chemotherapy-IO (15.4%). Overall survival (OS) and time-to-treatment failure of first-line therapy was identical for patients receiving first-line DAB/TRM (median OS 28.0 months) or chemo/IO (27.8 months, hazard ratio [HR] 1.1, p = 0.68). Female patients had superior OS (HR 0.65, p = 0.049, confirmed in multivariate model), which was mainly driven by superior OS of female to that of male patients receiving first-line DAB/TRM (OS HR 0.53, p = 0.015). There was no sex difference in survival of patients receiving IO-based first-line treatment (OS HR 1.02). Surprisingly, high PD-L1 status (tumor proportion score ≥50%) was associated with shortened time-to-treatment failure in first-line treatment (HR 1.83, p = 0.002, confirmed in multivariate models adjusting for sex; OS with nonsignificant trend, HR 1.4), regardless of whether the first-line regimen was IO-based or targeted therapy.</p><p><strong>Conclusions: </strong>Targeted or IO-based first-line treatment of BRAF-V600-mutated NSCLC has similar survival outcomes. Sex and PD-L1 status may support decision-making at the individual patient level.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks.","authors":"Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, Jose Carlos Benitez, Alice Durand, Helene Lasolle, Marine Perrier, Arnaud Jannin, Sandrine Laboureau, Maelle Le Bras, Olivier Chabre, Sébastien Gaujoux, Lionel Groussin Rouiller, Olivia Hentic, Hélène Du Boullay, Magalie Haissaguerre, Hervé Kinn, Thierry Lecomte, Pierre Goudet, Nicolas Girard, Jean-Yves Scoazec, Benjamin Besse, Matthieu Faron, Eric Baudin","doi":"10.1016/j.jtho.2025.04.013","DOIUrl":"10.1016/j.jtho.2025.04.013","url":null,"abstract":"<p><strong>Introduction: </strong>Thymic neuroendocrine tumors (Thy-NETs) constitute a poorly characterized ultrarare subgroup of NET. To characterize locally advanced or metastatic Thy-NET, to evaluate prognostic factors for survival, and to provide an overview of their current therapeutic management in two dedicated French national networks.</p><p><strong>Methods: </strong>Retrospective multicenter study of two French ENDOCAN-RENATEN and RYTHMIC networks.</p><p><strong>Results: </strong>A total of 74 patients (median age, 46 y) followed in 20 French centers between 1988 and 2020 were included. Main characteristics were as follows: male over female ratio of 2.7, multiple endocrine neoplasia type 1 inherited syndrome in 25 patients (34%), NET G2 atypical carcinoids in 31 patients (48%), 20 patients (31%) with NET G3 highly proliferative atypical carcinoids, and 11 patients (15%) with ectopic Cushing syndrome. Metastatic sites were as follows: lymph nodes (54 patients, 73%), bone (42 patients, 65%), lung (31 patients, 42%), and pleura (31 patients, 42%). A total of 64 patients (87%) had locally advanced Thy-NET and eight (11%) had synchronous metastases, at diagnosis. Pleural metastases were almost exclusively metachronous. Positive results for 18F-FDG or somatostain receptor imaging was found in 88% or 74% of cases, respectively. The 5-year overall survival was 85%. Univariate analysis on overall survival reveals a trend toward worse prognosis in case of female gender and bone metastases and better prognosis for patients with multiple endocrine neoplasia type 1. Partial responses were more frequently observed in patients treated with cytotoxic chemotherapy.</p><p><strong>Conclusion: </strong>This large series identifies specific characteristics of patients with advanced Thy-NET. Prognosis was better than previously reported. Perioperative pleural dissemination is suspected. Partial responses were mainly observed with chemotherapy.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.","authors":"Joshua K Sabari, Helena A Yu, Parthiv J Mahadevia, Yanfang Liu, Levon Demirdjian, Yen Hua Chen, Xiayi Wang, Antonio Passaro","doi":"10.1016/j.jtho.2025.04.010","DOIUrl":"10.1016/j.jtho.2025.04.010","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with NSCLC harboring EGFR mutations (EGFRm) have high mortality. The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC. We used longitudinal U.S. medical oncology databases to evaluate real-world overall survival (rwOS) and prognostic risk factor groups in advanced EGFRm NSCLC treated with first-line osimertinib.</p><p><strong>Methods: </strong>This retrospective, new-user cohort study used electronic records from ConcertAI, Flatiron Clinical-Genomics, and COTA databases. Patients with advanced or metastatic EGFRm NSCLC initiating osimertinib monotherapy in first line between April 1, 2018, and October 30, 2022, were included. Follow-up was until death or October 31, 2023. rwOS was estimated using the Kaplan-Meier method. Risk factors were evaluated using multivariate analysis.</p><p><strong>Results: </strong>A total of 1323 patients were included with a median follow-up of 20 months. Median age was 70 (range 35-89) years. Median rwOS was 28.6 months (95% confidence interval 26.8-30.9). In high-risk subgroups, median rwOS (mo) was 18.1 in patients with Eastern Cooperative Oncology Group score greater than or equal to 2, 24.3 with brain metastases, 19.3 with liver metastases, and 25.7 with TP53 co-mutation. In total, 95% of patients had at least one high-risk factor. Prevalence of Eastern Cooperative Oncology Group greater than or equal to 2 was 17%, brain metastases 36%, liver metastases 15%, and TP53 co-mutation 63%. Risk of death was significantly higher in patients with high-risk factors (p ≤ 0.011 for all). In total, 58% of patients survived to 2 years, 18% to 5 years, and 33% did not receive second-line therapy.</p><p><strong>Conclusion: </strong>Despite advances in tyrosine kinase inhibitor treatments, long-term survival of patients with advanced EGFRm NSCLC remains poor. Nearly all patients had risk factors for mortality and one-third did not receive second-line therapy.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial.","authors":"Shuai Wang, Min Zhu, Jihong Dong, Yong Zhang, Sushan Luo, Jiahao Jiang, Zhaozhao Cheng, Zhijun Li, Wenping Yang, Yue Yu, Zhengcheng Liu, Jiang Fan, Xiangnan Xu, Peipei Liu, Zhouao Zhang, Fang Can, Fei Liang, Xifei Jiang, Lijie Tan, Jianyong Ding","doi":"10.1016/j.jtho.2025.04.014","DOIUrl":"10.1016/j.jtho.2025.04.014","url":null,"abstract":"<p><strong>Introduction: </strong>This study reports the primary perioperative outcomes of efgartigimod in patients with thymoma-associated myasthenia gravis (TAMG).</p><p><strong>Methods: </strong>We conducted a prospective, single-arm clinical trial to evaluate the perioperative use of efgartigimod in acetylcholine receptor antibody-positive (AChR-Ab+) generalized TAMG. Efgartigimod was administered intravenously at a dose of 10 mg/kg on days 1, 8, 15, and 22, totaling four doses, with thymomectomy performed on day 9.</p><p><strong>Results: </strong>A total of 40 patients with TAMG were enrolled, with a median age of 46 years. The predominant thymomectomy approach was T2b minimally invasive thymectomy, performed in 21 of 40 patients (52.5%). All patients were classified as responders on the Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis, and Myasthenia Gravis Composite scale, demonstrating improvement across ocular, bulbar, limb, and respiratory muscle strength. At visit 4, myasthenic symptoms were obviously relieved, with reductions of 4.6 on Myasthenia Gravis Activities of Daily Living compared with baseline. Significant reductions were noted in both serum immunoglobulin G and AChR-Ab levels, without affecting other immunoglobulin classes or complement levels, after efgartigimod administration. The mean total postoperative hospitalization stay was 7.1 days. The total incidence of all-grade treatment-emergent adverse events was 62.5%, and the most treatment-emergent adverse events were reported to be mild. Postoperative myasthenic crisis occurred in four patients (10.0%) who underwent extended thymectomy.</p><p><strong>Conclusion: </strong>The satisfactory outcomes and rapid neurologic remission demonstrated efgartigimod had favorable safety and efficacy profiles during the perioperative period of thymomectomy for TAMG. These findings support the potential of efgartigimod as a novel perioperative treatment option for TAMG.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov identifier: </strong>NCT06221501.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer in Tanzania","authors":"Alex Mremi MD ,&nbsp;Jerry Ndumbalo MD ,&nbsp;Harrison Chuwa MD ,&nbsp;Oliver Henke MD ,&nbsp;Maximilian Rost MD","doi":"10.1016/j.jtho.2025.02.002","DOIUrl":"10.1016/j.jtho.2025.02.002","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages 560-564"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical Surgery in Pleural Mesothelioma: Houston, We Have a Problem","authors":"Jo Raskin MD,&nbsp;Jan van Meerbeeck MD, PhD,&nbsp;Paul Van Schil MD, PhD","doi":"10.1016/j.jtho.2025.01.022","DOIUrl":"10.1016/j.jtho.2025.01.022","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 5","pages":"Pages e59-e60"},"PeriodicalIF":21.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}